<div id="readability-page-1"><p>Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) have been given an average rating of &#34;Moderate Buy&#34; by the eighteen analysts that are  covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation, ten have given a buy recommendation and one  has given a strong buy recommendation to  the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $66.0625.</p><ul><li>3 Biotech Stocks That Could Benefit from the Patent Cliff</li></ul><p>CRSP has been the topic of several recent research reports. TD Cowen upped their target price on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a &#34;hold&#34; rating in a research note on Friday, February 13th. Citigroup increased their price objective on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, May 6th. Piper Sandler  reissued an &#34;overweight&#34; rating and issued a $110.00 price objective (up from $105.00) on shares of CRISPR Therapeutics in a research report on Tuesday, March 17th. Wall Street Zen raised shares of CRISPR Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday. Finally, Needham &amp; Company LLC increased their price objective on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, February 13th.</p><div><p><span></span><span>Get <strong>CRISPR Therapeutics</strong> alerts:</span></p></div><p><b>View Our Latest Analysis on CRSP</b></p><h2>CRISPR Therapeutics Price Performance</h2><ul><li>CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows</li></ul><p>Shares of CRSP opened at $54.01 on Tuesday. CRISPR Therapeutics has a fifty-two week low of $34.87 and a fifty-two week high of $78.48. The firm's 50 day moving average price is $52.18 and its 200 day moving average price is $54.13. The company has a market cap of $5.21 billion, a P/E ratio of -8.68 and a beta of 1.74. The company has a quick ratio of 17.96, a current ratio of 17.97 and a debt-to-equity ratio of 0.32. </p><p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%.The business had revenue of $1.46 million for the quarter.  On average, research analysts forecast that  CRISPR Therapeutics will post -5.07 earnings per share for the current fiscal year. </p><h2>Insider Buying and Selling at CRISPR Therapeutics</h2><ul><li>CRSPR Stock Could Be Ready to Deliver on Its Massive Promise</li></ul><p>In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 10,020 shares of the stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $468,735.60. Following the sale, the chief executive officer directly owned 255,501 shares of the company's stock, valued at approximately $11,952,336.78. This represents a 3.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Naimish Patel sold 3,150 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $48.26, for a total transaction of $152,019.00. Following the completion of the sale, the insider directly owned 13,143 shares in the company, valued at approximately $634,281.18. This represents a 19.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 51,828 shares of company stock valued at $2,578,097. Insiders own  4.10% of the company's stock. </p><h2>Institutional Investors Weigh In On CRISPR Therapeutics</h2><p>A number of large investors have recently modified their holdings of the company. Mcguire Capital Advisors Inc. purchased a new position in shares of  CRISPR Therapeutics in the 4th quarter valued at $25,000.  Ramirez Asset Management Inc. purchased a new position in shares of  CRISPR Therapeutics in the 4th quarter valued at $26,000.  Rothschild Investment LLC grew its position in shares of  CRISPR Therapeutics by 836.7% in the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company's stock valued at $29,000 after buying an additional 502 shares during the last quarter.  Thurston Springer Miller Herd &amp; Titak Inc. grew its position in shares of  CRISPR Therapeutics by 196.9% in the 4th quarter. Thurston Springer Miller Herd &amp; Titak Inc. now owns 576 shares of the company's stock valued at $30,000 after buying an additional 382 shares during the last quarter.  Finally, Optiver Holding B.V. grew its position in shares of  CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company's stock valued at $33,000 after buying an additional 210 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors. </p><h2>About CRISPR Therapeutics</h2> (Get Free Report)<p>CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.  </p><p>Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.</p><h2>See Also</h2><ul><li>Five stocks we like better than CRISPR Therapeutics</li><li>Before the Moon Base Gets Built, These 4 Companies Win</li><li>Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases</li><li>3 Stocks That Win If Inflation Surprises to the Downside</li><li>MercadoLibre Boldly Invests in Growth: Discount Deepens</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CRISPR Therapeutics Right Now?</h2><p>Before you consider CRISPR Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.</p><p>While CRISPR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CRSP

<p>CRISPR Therapeutics AG (NASDAQ:CRSP) has received an average analyst rating of "Moderate Buy" from eighteen analysts. The stock has two sell, five hold, ten buy, and one strong buy recommendations. The average 12-month price target is $66.06. Recent price targets include TD Cowen's hold rating at $45, Citigroup's buy rating at $82, and Piper Sandler's overweight rating at $110. The stock opened at $54.01, with a 52-week range of $34.87 to $78.48. The company reported a loss of $1.28 EPS for the last quarter and had revenue of $1.46 million.</p>

Market Beat

CRISPR Therap

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Wisdomtree BioRevolution Fund ETF

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

iShares Genomics Immunology and Healthcare ETF

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Toronto Dominion Bank

Citigroup

Piper Sandler Cos

CITIGROUP INC 6.250 NON CUM SER II PFD WI

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Moderate Buy" from Analysts